Published in Medical Letter on the CDC and FDA, January 3rd, 2010
"Subsequent single-arm and randomized clinical trials hove established the efficacy of plerixafor for autologous stem cell mobilization, both combined with granulocyte colony-stimulating factor (C-CSF) and as a single agent. In December 2008 the FDA approved plerixafor in combination with G-CSF for autologous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.